NorthWest Biotherapeutics Inc (NWBO)

[dmb2]

sentiment stocks, your point is a good one, the fact that IDH mutation was not always utilized to differentiate patient tumors renders the change in GBM definition less useful than it could be, unless they can successfully focus on a data subset where it was used, but they have to be careful since they are breaking new ground here and the complexity of the data is the main reason they have to wait for publication. Any further twisting or cross examining of data has to be done carefully.

The definition change can cause some noise in the data revelation and they do have to be prepared to address it, hopefully positively even qualitatively if not quantitatively. Knowing that IDH mutated patients were included presumably equally in all trials keeps the playing field even, the good news. The bad news is any crevice in their case may be used against their trial results to generate doubt.

Still all good in my opinion, and I believe they will be able to scientifically properly position this positively in their publication.

GLTA